Interlaboratory Reproducibility of Etest Amphotericin B and Caspofungin Yeast Susceptibility Testing and Comparison with the CLSI Method by Ranque, Stephane et al.
Interlaboratory Reproducibility of Etest Amphotericin
B and Caspofungin Yeast Susceptibility Testing and
Comparison with the CLSI Method
Stephane Ranque, L Lachaud, M Gari-Toussaint, A Michel-Nguyen, M Mallie´,
Jean Gaudart, S Bertout
To cite this version:
Stephane Ranque, L Lachaud, M Gari-Toussaint, A Michel-Nguyen, M Mallie´, et al.. Interlab-
oratory Reproducibility of Etest Amphotericin B and Caspofungin Yeast Susceptibility Testing
and Comparison with the CLSI Method. Journal of Clinical Microbiology, American Society
for Microbiology, 2012, <10.1128/JCM.00490-12>. <hal-01310344>
HAL Id: hal-01310344
https://hal-amu.archives-ouvertes.fr/hal-01310344
Submitted on 2 May 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0
International License
Interlaboratory Reproducibility of Etest Amphotericin B and
Caspofungin Yeast Susceptibility Testing and Comparison with the
CLSI Method
S. Ranque,a L. Lachaud,b M. Gari-Toussaint,c A. Michel-Nguyen,a M. Mallié,d J. Gaudart,e and S. Bertoutd
Parasitology and Mycology, CHU Timone, Aix-Marseille Université, Marseille, Francea; Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Nîmes,
Université Montpellier I, Montpellier, Franceb; Parasitology and Mycology, Archet 2 Hospital, Nice, Francec; UMI 233 Université Montpellier I/IRD/UCAD/UY1, TransVIHMI,
UFR Sciences Pharmaceutiques et Biologiques, Montpellier, Franced; and Aix-Marseille Université, LERTIM EA 3283, Marseille, Francee
This study aimed to assess the interlaboratory reproducibility at four university hospital laboratories in the southeast region of
France of the Etest technique for the determination of caspofungin (CAS) and amphotericin B (AMB)MICs and to compare it to
the CLSI broth microdilution reference method. Consecutive clinical yeast isolates (n 198) were included in the study. AMB
and CASMICs were read at 24 and 48 h. Interlaboratory reproducibility was estimated by using (i) an intraclass correlation coef-
ficient (ICC), (ii) essential agreement (EA), and (iii) categorical agreement (CA). For Etest interlaboratory reproducibility for
CAS, ICCs were 0.80 (95% confidence interval [CI], 0.76 to 0.84) and 0.81 (95% CI, 0.77 to 0.85) at 24 and 48 h, respectively. For
AMB, the ICCs were 0.51 (95% CI, 0.43 to 0.58) and 0.69 (95% CI, 0.63 to 0.74) at 24 and 48 h, respectively. At 48 h, the between-
center EAs ranged from 94.4 to 99.0% for both antifungals. For the comparison of the CLSI method and the Etest, the between-
technique ICCs were 0.69 (95% CI, 0.63 to 0.74) and 0.62 (95% CI, 0.55 to 0.68) for CAS and AMB, respectively. The EAs ranged
from 76.5 to 98.5% for CAS and from 90.3 to 97.4% for AMB according to the centers. CAs ranged from 87.9% to 91.4%, with
four very major errors for 2 strains (1 Candida albicans strain and 1 Candida krusei strain), for CAS and from 97.5 to 99.5%,
with four major errors, for AMB. In conclusion, the Etest showed a good interlaboratory reproducibility and a good correlation
with the CLSI technique. It is well suited for the routine clinical laboratory and can thus be used to monitor clinical yeast iso-
lates’ in vitro susceptibilities in this setting.
Since the 1990s, knowledge about the diversity of yeast speciesinvolved in human infections, the incidence of drug-resistant
isolates, and antifungal drug resistance mechanisms has signifi-
cantly increase (6, 10, 16, 24). In vitro susceptibility tests are based
on themeasurement of growthwith different drug concentrations
so as to determine theMIC for the population of a given isolate, an
in vitro-determined value that helps predict therapeutic efficacy
(1). This has been achieved with some degree of confidence by
using in vivomodels to determine clinical breakpoints in invasive
yeast infections, providing a useful indicator to guide therapeutic
choices (20). The reference tests for susceptibility testing are the
brothmicrodilution assays devised by the Clinical and Laboratory
Standards Institute (CLSI) and by the European Committee on
Antibiotic Susceptibility Testing (EUCAST) (5, 23). These refer-
ence methods are robust and reproducible; however, they remain
time-consuming and poorly suited for the routine clinical labora-
tory setting. Moreover, the MIC values for amphotericin B are
tightly clustered, and these methods rarely detect MIC values
above 1 mg/liter (2). To overcome these limitations, many com-
mercially available methods, such as the Etest, Sensititre Yeast-
One, or disk diffusion methods, that are easy to use in the routine
setting have been developed. These methods have been recently
incorporated into routine clinical laboratory practice and thus
generate a considerable amount of antifungalMIC data from clin-
ical fungal isolates. Presently, the monitoring of antifungal drug
susceptibility is usually restricted to national reference laborato-
ries that use broth microdilution assays to test clinical isolates
referred from collaborating clinical laboratories. These laborato-
ries thus collect invaluable data for the monitoring of susceptibil-
ity trends on national and international scales. However, there is a
need to develop antifungal susceptibility monitoring at a local or
regional scale. This complementary approach to the national ref-
erence centers could also improve patient care and generate sig-
nificant cost reductions given the prevalence of yeast infections,
their morbidity, and the costly protracted treatments required.
As a first step toward setting up a regional survey of in vitro
antifungal susceptibility in the southeast region of France, the pri-
mary aim of the present study was to assess the interlaboratory
reproducibility of MICs determined with the commercially avail-
able and routinely used Etestmethod for yeast isolated in first-line
clinical mycology laboratories of the four regional teaching hos-
pitals. The secondary aims were to validate the correlation of the
MICs of amphotericin B and caspofungin obtained with the Etest
and CLSI assays at 24 h and 48 h.
MATERIALS AND METHODS
The study was conducted by the Groupe d’Etude enMycologie du Sud de
la France (GEMSUD), a study group in medical mycology bringing to-
gether the parasitology and mycology laboratories of the four teaching
hospitals located in the southeast region of France, namely, Marseille,
Montpellier, Nice, and Nîmes.
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Yeast isolates. FromSeptember toNovember 2008, each participating
laboratory prospectively collected 50 yeast isolates cultured on Sabouraud
dextrose agar with antibacterials (gentamicin and chloramphenicol),
from distinct consecutive patients. Purity was checked by subculturing on
Chromagar Candida medium (Becton Dickinson, France), and the yeast
anamorphs were routinely identified by using routine methods. Finally,
200 Candida isolates were collected from different patient samples (Table
1). A total of 118 (59%) isolates were identified as Candida albicans, and
29 (15%) isolates were identified as Candida glabrata.
Antifungal susceptibility methods. TheMICs of amphotericin B and
caspofungin were determined by using both the CLSI and Etest assays.
The CLSI method was performed in one center (Faculty of Pharmacy,
Montpellier), while the Etest was performed in each of the four partici-
pating laboratories to determine amphotericin B and caspofungin MICs
for the 200 yeasts isolates. The isolates were anonymized by using distinct
labels for each center, thus allowing blinding to other centers’ test results.
The CLSI assay was performed as recommended previously (3, 5). The
Etest assay was performed as recommended by the manufacturer (AB
Biodisk, Sweden). Each assay was validated by using quality control
strains ATCC 22019 (Candida parapsilosis) and ATCC 6258 (Candida
krusei).
Statistical analysis.MIC data are presented as the range, MIC50, and
MIC90 for each species.
The interlaboratory reproducibility of the Etest assay was evaluated by
calculating the intraclass correlation coefficient (ICC) and its 95% confi-
dence interval (CI), which measure the consistency of the MIC values
between the centers, aswell as the essential agreement (EA)within2 log2
dilutions for both amphotericin B and caspofungin. The MICs were log
transformed to approximate a normal distribution. The ICC is a reverse
measurement of the variability of a quantitative variable; it has a maxi-
mum value of 1 if there is a perfect correlation and a minimum value of 0
if there is a complete absence of a correlation. The ICC is the coefficient
which has the highest statistical power for correlation studies (14).
The overall agreement between the results of the Etest and the CLSI
assays at 48 h was measured by using the ICC and the categorical agree-
ment (CA). The interpretative breakpoints used for amphotericin B were
susceptible at1 mg/liter and resistant at1 mg/liter (2). For caspofun-
gin, the new interpretative breakpoints proposed by Pfaller et al. (19) for
C. albicans, C. glabrata, C. tropicalis, C. krusei, C. parapsilosis, and C. guil-
liermondii were used for the CLSI method; for other species, and as rec-
ommended by themanufacturer for the Etest method, a 2-mg/liter break-
point was used (susceptible at 2 mg/liter and not susceptible at 2
mg/liter) (3). A verymajor error (VME) occurredwhen an isolate that was
determined to be resistant by the reference CLSI assay was categorized as
susceptible by the Etest assay in at least one center. A major error (ME)
occurred when an isolate that was determined to be susceptible by the
TABLE 1 Characteristics of the yeast isolates collected in different centers
Isolate characteristic
No. (%) of isolates collected in:
Total no. (%) of
isolates collectedMarseille Montpellier Nice Nîmes
Species
C. albicans 29 (58) 31 (62) 37 (74) 21 (42) 118 (59)
C. glabrata 4 (8) 5 (10) 5 (10) 15 (30) 29 (15)
C. parapsilosis 6 (12) 4 (8) 0 (0) 6 (12) 16 (8)
C. tropicalis 3 (6) 4 (8) 2 (4) 4 (8) 13 (7)
C. krusei 3 (6) 3 (6) 3 (6) 1 (2) 10 (5)
C. lusitaniae 1 (2) 2 (4) 0 (0) 1 (2) 4 (2)
C. kefyr 1 (2) 0 (0) 2 (4) 0 (0) 3 (2)
Others 3 (6) 1 (2) 1 (2) 2 (4) 7 (4)
C. famata 1 1
C. rugosa 1 1
C. guilliermondii 1 1
C. dublininensis 1 1
C. inconspicua 1 1
C. sake 1 1
C. sphaerica 1 1
Wards
Medicine 20 (40) 18 (36) 16 (32) 16 (32) 70 (35)
Intensive care 8 (16) 15 (30) 5 (10) 15 (30) 43 (22)
Oncology-hematology 9 (18) 2 (4) 11 (22) 4 (8) 26 (13)
Surgery 9 (18) 7 (14) 6 (12) 3 (6) 25 (13)
Gynecology 0 (0) 2 (4) 4 (8) 7 (14) 13 (7)
Infectious diseases 0 (0) 3 (6) 4 (8) 5 (10) 12 (6)
Pediatrics 4 (8) 3 (6) 4 (8) 0 (0) 11 (6)
Specimens
Lower respiratory tract 30 (60) 16 (32) 20 (40) 5 (10) 71 (36)
Urine 2 (4) 17 (34) 8 (16) 16 (32) 43 (22)
Upper respiratory tract 6 (12) 4 (8) 5 (10) 9 (18) 24 (12)
Stools 4 (8) 3 (6) 7 (14) 6 (12) 20 (10)
Skin 2 (4) 3 (6) 2 (4) 5 (10) 12 (6)
Vaginal 0 (0) 0 (0) 4 (8) 6 (12) 10 (5)
Digestive tract 2 (4) 1 (2) 2 (4) 2 (4) 7 (4)
Normally sterile fluids 1 (2) 3 (6) 2 (4) 1 (2) 7 (4)
Tissues (biopsy specimens) 2 (4) 2 (4) 0 (0) 0 (0) 3 (2)
Blood 1 (2) 1 (2) 0 (0) 0 (0) 2 (1)
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CLSI assay was categorized as resistant by the Etest assay. A minor error
(mE) occurred when an isolate that was determined to have intermediate
resistance by the CLSI assay was categorized as either sensitive or resistant
by the Etest assay. The EA and CA were analyzed at 48 h.
The effect of the yeast species on amphotericin B and caspofungin
MICs was tested by using analysis of variance (ANOVA) with Tukey post
hoc tests to control the type I error. Analyses were performed with SPSS
17.0.2 statistical software (SPSS Inc.); all tests were two sided, and a P
value of0.05 was considered statistically significant.
RESULTS
Details of hospitalization wards, specimens, and Candida species
collected by the different centers are presented in Table 1. Most of
the Candida strains were isolated in lower respiratory tract (36%)
and urine (22%) specimens from patients hospitalized in medical
wards. As expected,Candida albicanswas the predominant species
(59%). Finally, MIC results for caspofungin and amphotericin B
for the four centers could be analyzed for 198 isolates by using
bothmethods. TheMIC values of the three quality controls strains
were within the expected value for each experiment and both an-
tifungals with the Etest and the CLSI method.
Etest interlaboratory reproducibility. Caspofungin MIC val-
ues at 24 h were (i) lower than 0.25 mg/liter for all the C. albicans
isolates by both the CLSI and Etest assays in 2 centers and (ii)
higher than 0.12mg/liter for 1 to 10C. glabrata strains by the Etest
assay (depending on the center) and at least 0.25mg/liter for 13C.
glabrata strains by the CLSI assay. At 48 h, 10 strains (1C. albicans,
2 C. glabrata, and 7 C. krusei strains) were categorized as being
resistant to caspofungin by at least one method in at least one
center. At 48 h, caspofunginMIC50 andMIC90 values ranged from
0.047 to 0.125 mg/liter and from 0.38 to 0.75 mg/liter, respec-
tively, whatever the species (Table 2). For all centers, caspofungin
MIC90 values were1 mg/liter for all species except for Candida
parapsilosis, where the caspofungin MIC50 and MIC90 ranged
from 0.5 to 1 mg/liter and from 0.75 to 1.5 mg/liter, respectively.
The overall Etest interlaboratory reproducibility was highly signif-
icant (P  104) for caspofungin, with ICCs of 0.80 (95% CI,
0.761 to 0.842) and 0.81 (95% CI, 0.771 to 0.846) at 24 and 48 h,
respectively. Noticeably, 24 or 48 h of incubation did not signifi-
cantly impact the reproducibility of Etest caspofungin MICs. The
2-by-2 center EA of caspofungin MICs ranged from 95.48% to
98.99%, with a mean EA of 97.06%.
Amphotericin MIC values were 1 mg/liter in at least one
center for 3 and 15 Candida isolates at 24 h and 48 h, respectively.
MICs of1 mg/liter were reported by more than one center for 4
of these 15 isolates; for the 11 remaining isolates, this MIC of1
mg/liter was a single-center finding. At 48 h, amphotericin MIC50
and MIC90 values ranged from 0.125 to 0.25 mg/liter and from
0.38 to 0.75mg/liter, respectively, whatever the species considered
(Table 2).With regard toC. krusei, themeanMIC values by center
ranged from 0.75 to 1.85 mg/liter. The overall Etest interlabora-
tory reproducibility of amphotericin B testing was relatively lower
than that for caspofungin and higher at 48 h than at 24 h, with
ICCs of 0.509 (95% CI, 0.433 to 0.584) and 0.687 (95% CI, 0.630
to 0.740) at 24 and 48 h, respectively. The 2-by-2 center EA of
amphotericinMICs ranged from94.42 to 98.99%,with ameanEA
of 97.54%.
Comparison of Etest and CLSI results. The between-tech-
nique ICCs were 0.69 (95% CI, 0.63 to 0.74) and 0.62 (95% CI,
0.55 to 0.68) for CAS and AMB, respectively. EAs ranged from
76.5 to 98.5% for CAS and from 90.3 to 97.4% for AMB according
to the centers. All isolates were categorized as being susceptible to
amphotericin B by both the CLSI and Etest assays at 24 h of incu-
bation whatever the center. Hence, the CA was perfect at 24 h and
ranged from 97.5 to 99.5%, with four major errors at 48 h, de-
pending on the center. The discrepancies are detailed in Table 3,
with five major errors corresponding to four isolates (three C.
krusei isolates and oneC. parapsilosis isolate) thatwere categorized
as sensitive by the CLSI method and resistant by the Etest.
For caspofungin, the CAs between the Etest and CLSImethods
were very similar whatever the center and ranged from 88.38 to
88.88%. Seven very major errors (VME) were observed: one C.
albicans isolate was categorized as being resistant (MIC  1 mg/
liter) by the CLSI assay and sensitive (MIC 0.047 or 0.094 mg/
liter) by the Etest method in the four laboratories (Table 4), and
TABLE 2 Amphotericin B and caspofungin MIC50s and MIC90s obtained with the CLSI method and the Etest method in the four centers at the 48-h
endpoint reading according to Candida species
Drug and
Candida sp.
No. of
isolates
MIC value (mg/liter)
CLSI test at 48 h
Etest
Marseille Montpellier Nice Nîmes
MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90 MIC range MIC50 MIC90
Amphotericin B
C. albicans 117 0.125–1 0.25 0.5 0.047–0.25 0.125 0.19 0.047–0.38 0.19 0.25 0.032–1 0.19 0.25 0.047–0.38 0.19 0.25
C. glabrata 28 0.125–1 0.5 1 0.064–0.5 0.25 0.5 0.125–1 0.5 0.75 0.094–1.5 0.38 1 0.125–0.75 0.38 0.5
C. krusei 10 0.5–1 1 1 0.5–1.5 0.75 1 1.5–3 1.5 3 0.064–3 1 2 0.38–2 0.5 1.5
C. parapsilosis 16 0.25–1 0.5 1 0.125–0.75 0.38 0.5 0.25–4 0.5 1 0.064–0.75 0.25 0.75 0.25–1 0.5 1
C. tropicalis 13 0.06–1 1 1 0.094–.38 0.125 0.38 0.094–1.5 0.38 0.75 0.064–0.5 0.19 0.38 0.032–0.5 0.19 0.38
Others 14 0.03–1 0.25 0.5 0.047–0.38 0.125 0.38 0.047–0.5 0.125 0.5 0.016–0.5 0.125 0.38 0.032–0.5 0.125 0.38
All species 198 0.03–1 0.25 1 0.047-1.5 0.125 0.38 0.047–4 0.25 0.75 0.016–3 0.19 0.5 0.032–2 0.19 0.5
Caspofungin
C. albicans 117 0.125–1 0.125 0.25 0.016–0.38 0.047 0.094 0.032–1.5 0.094 0.19 0.016–0.38 0.064 0.125 0.016–0.25 0.032 0.064
C. glabrata 28 0.125–0.25 0.25 0.25 0.094–0.38 0.125 0.19 0.094–0.38 0.19 0.25 0.094–0.64 0.125 0.38 0.047–0.25 0.125 0.125
C. krusei 10 0.25–1 0.5 0.5 0.38–0.75 0.5 0.75 0.5–3 0.75 1 0.25–1 0.5 1 0.125–0.75 0.38 0.5
C. parapsilosis 16 0.125–1 0.5 1 0.19–1 0.5 1 0.5–1.5 1 1.5 0.094–0.75 0.38 0.75 0.38–32 0.38 1
C. tropicalis 13 0.125–0.5 0.125 0.4 0.047–0.19 0.064 0.19 0.064–0.38 0.125 0.25 0.064–0.25 0.125 0.19 0.032–0.38 0.094 0.125
Others 14 0.125–0.5 0.25 0.5 0.032–0.5 0.094 0.5 0.064–1.5 0.19 0.5 0.016–1.5 0.125 0.25 0.016–0.5 0.64 0.38
All species 198 0.125–1 0.125 0.5 0.016–1 0.064 0.38 0.032–3 0.125 0.5 0.016–1.5 0.094 0.38 0.016–32 0.047 0.38
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one C. krusei isolate was resistant (MIC 1 mg/liter) by the CLSI
assay and sensitive (MIC 0.38 mg/liter) by the Etest method in
three laboratories. Using the interpretative breakpoints proposed
previously by Pfaller (19) for the Etest method, the CA ranged
from 87.87 to 91.41%, with three VME (Table 4).
Interspecies MIC differences. Amphotericin B and caspofun-
gin MICs determined by the CLSI method and Etest at 48 h were
statistically different with respect to yeast species (P  104).
Caspofungin MICs could be split into two homogeneous groups
by using Tukey post hoc tests. The caspofungin MICs were signif-
icantly higher for C. krusei and C. parapsilosis than for the group
that included all other yeast species. Amphotericin B MICs could
be split into three groups with statistically significantly increasing
MIC values: the group (referred to as “others” in Table 2) that
included all rarely isolated species with relatively low amphoteri-
cin B MICs; the group that included C. albicans, C. glabrata, C.
kefyr, C. parapsilosis, and C. tropicalis; and, lastly, C. krusei species
for which MICs were significantly higher than those for the two
other groups. Indeed, the 10 C. krusei isolates studied displayed
relatively elevated MICs for amphotericin B, as shown in Table 2.
DISCUSSION
The good interlaboratory reproducibility of theMICs obtained by
using Etest yeast antifungal sensitivity testing, as evidenced by our
findings, paves theway toward a clinical laboratory-based regional
survey of antifungal drug susceptibility. The good interlaboratory
reproducibility of Etest susceptibility testing of azoles was estab-
lished previously by Matar et al. (12). Our findings for amphoter-
icin B Etest susceptibility testing are in line with those reported
previously by Pfaller et al. (22). However, this study is the first to
report the interlaboratory reproducibility of Etest susceptibility
testing of caspofungin. This study’s design had both strengths and
limitations. On the one hand, the isolates studied were represen-
tative of the routine activity in clinical laboratories of teaching
hospitals; on the other hand, the CA analysis was poorly informa-
tive, becausemost of the strains studied had “wild-type”MICs and
thus were very seldom classified as resistant. The Etest MICs were
also highly correlated to those obtained with the CLSI assay. For
the Etest method, we also demonstrated that whatever the break-
points considered, the CAs between both methods were very
good, and the VME observed in both cases corresponded to the
same isolates, oneC. albicans isolate and oneC. krusei isolate. This
excellent correlation between the CLSI and the Etest assays for
caspofungin in vitro susceptibility testing was in keeping with that
reported previously by others (18). However, this correlation was
overall lower for amphotericin B than for caspofungin, in linewith
data reported previously by Fleck et al. (7), who found 89% and
98% EAs for amphotericin B and caspofungin, respectively. With
a different study design and comparing the Etest to the EUCAST
broth dilution assay, Dannaoui et al. (4) previously found a 75%
TABLE 3 Details of amphotericin B MICs of five isolates that displayed
one major categorical error in at least one center with the Etest or CLSI
methoda
Species
MIC (mg/liter) determined by:
Etest
CLSI
methodMontpellier Marseille Nice Nîmes
C. krusei 1.5 1.5 1 0.5 1
C. krusei 2 0.75 2 0.38 1
C. parapsilosis 4 0.25 0.19 0.75 0.5
C. krusei 3 0.75 3 2 1
a Outlying MICs are underlined.
TABLE 4 Details of categorical agreement errors for caspofungin testing by Eteste in each center compared to the CLSI reference method, using new
interpretative breakpoints depending on speciesf
Testing site
Categorical
errorg
No. of isolates with error
Total no. of
errors
Categorical
agreement (%)
C. albicans
(n 116)
C. glabrata
(n 28)
C. krusei
(n 10)
C. tropicalis
(n 13)
C. parapsilosis and
others (n 31)
Montpellier mE 0 15 5b 1d 0 22 88.88
ME 0 0 0 0 0
VME 1a 0 0 0 0
Marseille mE 0 15 5b 1d 0 23 88.38
ME 0 0 0 0 0
VME 1a 0 1c 0 0
Nice mE 0 15 5b 1d 0 23 88.38
ME 0 0 0 0 0
VME 1a 0 1c 0 0
Nîmes mE 0 15 5b 1d 0 23 88.38
ME 0 0 0 0 0
VME 1a 0 1c 0 0
a The same C. albicans isolate in the 4 centers.
b The same C. krusei isolates in the 4 centers.
c The same C. krusei isolate in 3 centers.
d The same C. tropicalis isolate in the 4 centers.
e Considered breakpoint of 2 mg/liter.
f See reference 19.
g mE, minor error; ME, major error; VME, very major error.
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EA for both drugs and 77% and 88% CAs for amphotericin B and
caspofungin, respectively.
Unsurprisingly, we found elevatedMICs of caspofungin for C.
parapsilosis, since it is known that the usually significantly higher
MICs of caspofungin are the consequence of a recently identified
functional pointmutation in the Fks1 gene of this species (8). Our
finding of significantly elevated caspofungin MICs for C. krusei
was also in keeping with previous reports by others (17, 19). Note-
worthy, theMIC50 of the 10C. krusei strains studied encompassed
the newly revised CLSI clinical breakpoints defining caspofungin
resistance at anMIC of0.5mg/liter (19). Furthermore,C. krusei
displayed significantly higher MICs of amphotericin B, as evi-
denced by the results of the Etest but not the CLSI assay. The
discrepancy between the results of these two assays is in keeping
with the fact that amphotericin B resistance ismore easily detected
by the Etest than by broth microdilution techniques (11, 21). The
emergence of a multidrug resistance profile of C. krusei was re-
cently reported (17). Fortunately, this species remains relatively
infrequently isolated in the clinical setting (9, 13, 15).
In conclusion, our findings for amphotericin B and caspofun-
gin indicate that Etest susceptibility testing results are reproduc-
ible between laboratories and correlate well with the results of the
reference broth microdilution CLSI technique. The Etest assay is
well suited to the routine clinical laboratory and can thus be used
in this setting to monitor the in vitro susceptibilities of clinical
yeast isolates. Altogether, these findings strongly support the rel-
evance of implementing hospital laboratory-based regional mon-
itoring of yeast epidemiology and Etest-based antifungal drug sus-
ceptibility.
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